In this article, we will discuss Durvalumab (Warnings-36). So, let’s get started.
Embryo-Fetal Toxicity
Based on its mechanism of action and data from animal studies, Durvalumab can cause fetal harm when administered to a pregnant woman. In animal studies, administration of durvalumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in increased premature delivery, fetal loss and premature neonatal death. Advise pregnant women of the potential risk to a fetus. Advise females to use effective contraception during treatment with Durvalumab and for at least 3 months after the last dose of Durvalumab.